Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia

Hurk, Corina van den; Breed, W.P.M.; Nortier, J.W.R.

doi:10.1007/s00520-012-1465-0

Cited by 48 publications

(57 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, SC should not be offered to patients with chemotherapy schedules in which chances of hair preservation are minimal;[21] Hair loss in spite of using SC causes an extra burden for patients and it tends to cause a deteriorated body image and quality of life. [2] Patient tolerance of SC was high and in accordance with the literature,[1422] but it was underestimated by nurses and MDs.…”

Section: Resultssupporting

confidence: 71%

“…[24] However, CIA appeared to be an important side-effect of cancer treatment for males too[326] and, when SC was actively offered to them, 37%[22] to 57%[23] chose it. Again, this shows the need for improved information provision.…”

Section: Resultsmentioning

confidence: 99%

“…SC efficacy is high for taxanes, but decreases when used in combination with anthracyclines. [17212223] Overall, 50% of the patients are satisfied with their hair preservation. [1421]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals

Peerbooms

Hurk

Breed

2015

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Objective:Scalp cooling (SC) is applied to reduce chemotherapy-induced alopecia (CIA). The aim of this study was to investigate patients’ familiarity and opinions and oncological professionals’ attitude and knowledge about SC in the Netherlands.Methods:Ex breast cancer patients, nurses and medical oncologists (MDs) from SC and non-SC hospitals filled out questionnaires.Results:The majority of MDs and nurses were satisfied with the results of SC, as were SC patients. Over 33% of MDs and nurses perceived their knowledge level insufficient to inform patients about effectiveness, which was over 43% for information about safety. MDs main reason to not apply SC was doubt about effectiveness and safety. Nurses generally offered SC to a minority of eligible patients. Patients were frequently unfamiliar with SC before diagnosis. Seventy percent of SC patients with insufficient results (20/52) reported to mind it very much. With expected success rates of 35% and 50%, respectively, 36% and 54% of patients would use SC again.Conclusion:Room for improvement has been shown for both patients’ familiarity and oncological professionals’ knowledge about SC. Sharing knowledge about results, safety and patients’ experiences will improve patient counseling and SC availability. The results of this survey led to the development of a national standard on CIA and SC.

show abstract

Section: Resultssupporting

confidence: 71%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals

Peerbooms

Hurk

Breed

2015

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…A subsequent study by the same authors found that a shorter post-infusion cooling time was as effective as a longer post-infusion cooling time (45 vs. 90 minutes). 72 …”

Section: Chemotherapy-induced Alopeciamentioning

confidence: 99%

“…107, 108 Although the ideal technique for cooling has yet to be elucidated, recent reports have yielded promising data regarding the optimal degree of cooling necessary 55 and the duration of post-infusion cooling. 72, 74 Further studies comparing different cooling techniques are needed. Finding more user-friendly means of providing effective scalp hypothermia would be helpful.…”

Section: Conclusion For Supportive Cryotherapymentioning

confidence: 99%

Supportive Cryotherapy: A Review From Head to Toe

Kadakia

Rozell

Butala

et al. 2014

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Context Conventional chemotherapy leads to multiple adverse mucocutaneous complications including oral mucositis, alopecia, ocular toxicity, and onycholysis. Limited pharmacologic interventions are available for preventing these clinical problems. Objectives This study aimed to critically review the role of cryotherapy (regional hypothermia) for alleviating these adverse symptoms. Methods A narrative review was performed, with an emphasis on randomized controlled trials. A comprehensive search using PubMed, Ovid, Embase, and MEDLINE® was completed. References of all cited articles also were reviewed. Data from the review were comprised of articles published between 1970 to May 2013. Results Available evidence suggests that regional hypothermia decreases the burden of chemotherapy-related oral mucositis, alopecia, ocular toxicity, and onycholysis. The major limitations of studies include the absence of blinded control groups and variable clinical endpoints. Conclusion Regional hypothermia decreases the burden of these four chemotherapy-induced complications and is well tolerated. More research is needed to determine what subgroups of cancer patients are most likely to respond to different types of regional hypothermia, the ideal duration of cooling needed, and to further improve the ease of use of the cooling devices.

show abstract

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Rugo

Klein

Melin

et al. 2017

JAMA

141

103

View full text Add to dashboard Cite

IMPORTANCE Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited.OBJECTIVES To evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes in quality of life. DESIGN, SETTING, AND PARTICIPANTSA prospective cohort study conducted at 5 US medical centers of women with stage I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential or combination anthracycline and taxane (106 patients in the scalp cooling group and 16 in the control group; 14 matched by both age and chemotherapy regimen). The study was conducted between August 2013 and October 2014 with ongoing annual follow-up for 5 years.EXPOSURES Use of a scalp cooling system. Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward.MAIN OUTCOMES AND MEASURES Self-estimated hair loss using the Dean scale was assessed 4 weeks after the last dose of chemotherapy by unblinded patient review of 5 photographs. A Dean scale score of 0 to 2 (Յ50% hair loss) was defined as treatment success. A positive association between scalp cooling and reduced risk of hair loss would be demonstrated if 50% or more of patients in the scalp cooling group achieved treatment success, with the lower bound of the 95% CI greater than 40% of the success proportion. Quality of life was assessed at baseline, at the start of the last chemotherapy cycle, and 1 month later. Median follow-up was 29.5 months. RESULTS Among the 122 patients in the study, the mean age was 53 years (range, 28-77 years); 77.0% were white, 9.0% were black, and 10.7% were Asian; and the mean duration of chemotherapy was 2.3 months (median, 2.1 months). No participants in the scalp cooling group received anthracyclines. Hair loss of 50% or less (Dean score of 0-2) was seen in 67 of 101 patients (66.3%; 95% CI, 56.2%-75.4%) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0%) in the control group (P < .001). Three of 5 quality-of-life measures were significantly better 1 month after the end of chemotherapy in the scalp cooling group. Of patients who underwent scalp cooling, 27.3% (95% CI, 18.0%-36.6%) reported feeling less physically attractive compared with 56.3% (95% CI, 31.9%-80.6%) of patients in the control group (P = .02). Of the 106 patients in the scalp cooling group, 4 (3.8%) experienced the adverse event of mild headache and 3 (2.8%) discontinued scalp cooling due to feeling cold.CONCLUSIONS AND RELEVANCE Among women undergoing non-anthracycline-based adjuvant chemotherapy for early-stage breast cancer, the use of scalp cooling vs no scalp cooling was associated with less hair loss at 4 weeks after the last dose of chemotherapy. Further research is ne...

show abstract

Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia

Cited by 48 publications

References 26 publications

Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals

Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals

Supportive Cryotherapy: A Review From Head to Toe

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Contact Info

Product

Resources

About